文献速递临床试验与 GCP基础与转化研究

神经内分泌肿瘤肝转移栓塞治疗随机试验(RETNET)研究方案

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-07-17

RETNET 是一项前瞻性、开放标签、多中心随机对照试验,针对进展性或症状性不可切除的神经内分泌肿瘤肝转移患者,比较单纯栓塞、碘油化疗栓塞和药物洗脱微球化疗栓塞三种技术。主要终点为初始栓塞治疗后的肝脏无进展生存期(HPFS),每臂计划入组60例,样本量按检测化疗栓塞对比单纯栓塞的HPFS风险比1.78进行把握度计算。

要点

  • 比较单纯栓塞、碘油化疗栓塞和药物洗脱微球化疗栓塞三种技术。
  • 主要终点为RECIST标准评估的肝脏无进展生存期(HPFS)。
  • 每臂60例,按检测HR为1.78进行样本量把握度计算。

核心结论

  • RETNET试验旨在确定神经内分泌肿瘤肝转移的最佳栓塞治疗技术。

研究设计与样本

  • 前瞻性、开放标签、多中心随机对照试验。
  • 纳入进展性或症状性不可切除的神经内分泌肿瘤肝转移患者。
  • 随机分配至单纯栓塞、碘油化疗栓塞或药物洗脱微球化疗栓塞组,每臂60例。
  • 主要终点为初始栓塞治疗后按RECIST标准评估的肝脏无进展生存期(HPFS)。
  • 样本量按检测化疗栓塞对比单纯栓塞的HPFS风险比1.78进行把握度计算,基于现有回顾性研究估计。

关键数值与推荐

  • 每臂入组60例。
  • 主要终点HPFS的风险比假设为1.78(化疗栓塞对比单纯栓塞)。
  • 每臂10例和30例时进行中期安全性分析。

临床怎么用

  • 当前指南推荐对进展性或症状性NET肝转移行栓塞治疗,但最佳技术尚不明确。
  • RETNET试验结果将为临床选择栓塞技术提供随机对照证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuroendocrine tumors (NETs) are the second most common gastrointestinal malignancy after colon cancer. Up to 90% of patients with NETs develop liver metastases, which are a major determinant of symptoms and survival. Current guidelines recommend embolotherapy for progressive or symptomatic NET liver metastases, but the optimal technique among bland embolization, lipiodol chemoembolization, and drug-eluting bead chemoembolization remains unknown and controversial. METHODS/DESIGN: A prospective, open-label, multicenter randomized controlled trial will be conducted in patients with progressive or symptomatic unresectable NET liver metastases. Patients will be randomized to treatment with bland embolization, lipiodol chemoembolization, or drug-eluting microsphere chemoembolization, with 60 enrollees per arm. The primary endpoint will be hepatic progression-free survival (HPFS) following initial embolotherapy by RECIST criteria. The sample size is powered to detect an HR of 1.78 for HPFS following chemoembolization compared with bland embolization, which was estimated on the basis of existing retrospective studies. Secondary endpoints include overall progression-free survival, duration of symptom control, quality of life, rate of adverse events, and interval between embolotherapy cycles. Interim safety analyses will be performed at 10 and 30 patients per arm. DISCUSSION: The RETNET trial is a prospective, multicenter randomized controlled trial designed to determine the optimal embolotherapy technique for NET liver metastases. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02724540 . Registered on March 31, 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen JX, Wileyto EP, Soulen MC, et al. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30016989. doi:10.1186/s13063-018-2782-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。